

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Patent Nos.: See attached "Exhibit 1"

Sir:

**REVOCATION OF POWER OF ATTORNEY  
STATEMENT UNDER 37 C.F.R. § 3.73(b)  
AND GRANT OF NEW POWER OF ATTORNEY**

The undersigned, a representative authorized to sign on behalf of the assignee owning all of the interest in the patents and applications described/listed herein, hereby revokes all previous powers of attorney or authorization of agent granted in this application before the date of execution hereof.

As required by 37 C.F.R. § 3.73(b), the undersigned verifies that Nanotherapeutics, Inc. is the assignee of the entire right, title, and interest in each of the patents and applications listed on the attached Exhibit 1 by virtue of a patent assignment from Vion Pharmaceuticals, Inc. recorded in the U.S. Patent and Trademark Office at Reel 026235, Frame 0568.

The undersigned representative of the Assignee hereby grants its power of attorney to the patent practitioners associated with **FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.**, Customer Number 22,852, to prosecute these applications and to transact all business in the Patent and Trademark Office connected therewith, and to receive the Letters Patents.

Please send all future correspondence concerning this application to Finnegan,  
Henderson, Farabow, Garrett & Dunner, L.L.P., Customer No. 22,852.

Dated: \_\_\_\_\_

6/1/11

By: \_\_\_\_\_

James Talton, Ph.D., CEO  
Nanotherapeutics, Inc.

**EXHIBIT 1**

PATENT  
Customer No. 22,852

<b>Appln. No./ Appln. Date</b>	<b>Title</b>	<b>Patent No./Date</b>
09/645,418 08/24/2000	Compositions and Methods for Delivery of an Agent Using Attenuated Salmonella Containing Phage	
09/679,454 10/04/2000	Non-Invasive Tumor Imaging by Tumor-Targeted Bacteria	
10/076,117 02/13/2002	Compositions and Methods for Delivery of an Agent Using Attenuated Salmonella Containing Phage	
10/790,586 03/01/2004	Compositions and Methods for Delivery of an Agent Using Attenuated Salmonella Containing Phage	
10/738,423 12/16/2003	Compositions and Methods for Tumor-Targeted Delivery of Effector Molecules	
11/627,743 01/26/2007	Compositions and Methods for Tumor-Targeted Delivery of Effector Molecules	
12/080,357 04/02/2008	Phosphate-Bearing Prodrugs of Sulfonyl Hydrazines as Hypoxia- Selective Antineoplastic Agents	
12/254,122 10/20/2008	Compositions and Methods for Tumor-Targeted Delivery of Effector Molecules	
60/157,500 10/04/1999	Compositions and Methods for the Tumor-Targeted Delivery of Anti-Angiogenic Factors	

**EXHIBIT 1**

PATENT  
Customer No. 22,852

Appln. No./ Appln. Date	Title	Patent No./Date
60/157,581 10/04/1999	Compositions and Method for Tumor-Targeted Bacteriocin Delivery	
60/157,620 10/04/1999	Non-Invasive Tumor Imaging by Tumor-Targeted Bacteria	
60/157,637 10/04/1999	Compositions and Methods for Tumor-Targeted TNF Delivery	
60/240,529 10/13/2000	Modified Prodrug Forms of AP/AMP	
60/352,259 01/28/2002	Methods for Treating Cancer by Administering Tumor-Targeted Bacteria and an Immunomodulatory Agent	
60/549,598 03/03/2004	Novel Hydrazone and Imine Compounds as Anti-Cancer Agents	
60/549,950 03/04/2004	Method of Treating Ischemia, Reperfusion, Myocardial Infarction and Other Cardiovascular Conditions and Disease States	
60/551,981 03/10/2004	Method of Treating Ischemia, Reperfusion, Myocardial Infarction and Other Cardiovascular Conditions and Disease States	
60/611,623 09/21/2004	Phosphate-Bearing Prodrugs of Sulfonyl Hydrazines as Hypoxia- Selective Antineoplastic Agents	

**EXHIBIT 1**

PATENT  
Customer No. 22,852

Appln. No./ Appln. Date	Title	Patent No./Date
60/615,419 10/01/2004	Phosphate-Bearing Prodrugs of Sulfonyl Hydrazines as Hypoxia- Selective Antineoplastic Agents	
60/616,500 10/06/2004	Phosphate-Bearing Prodrugs of Sulfonyl Hydrazines as Hypoxia- Selective Antineoplastic Agents	
60/660,356 03/10/2005	(Purin-6-yl) - Hydrazones as Novel Inhibitors of Protein Tyrosine Kinases	
60/660,357 03/10/2005	Novel Hydrazone and Imine Compounds as Anti-Cancer Agents	
60/660,738 03/11/2005	Alkylguanyltransferase Assays	
60/663,454 03/18/2005	Alkylguanyl Transferase Assays	
60/781,866 03/13/2006	Novel Hydrazones as Inhibitors of Protein Tyrosine Kinases	
60/906,896 03/14/2007	Novel Hydrazones as Inhibitors of Protein Tyrosine Kinases	
60/931,528 05/24/2007	Methods of Synthesizing VNP4010M	
61/128,975 05/27/2008	Methods of Synthesizing VNP4010M	
10/950,890 09/27/2004	Water-Soluble SHPS as Novel Alkylating Agents	
08/856,568 05/15/1997	Prodrug Forms of Ribonucleotide Reductase Inhibitors 3-AP and 3-AMP	5,767,134 06/16/1998

**EXHIBIT 1**

PATENT  
Customer No. 22,852

<b>Appln. No./ Appln. Date</b>	<b>Title</b>	<b>Patent No./Date</b>
08/856,559 05/15/1997	Process for the Synthesis of Ribonucleotide Reductase Inhibitors 3-AP and 3-AMP	5,869,676 02/09/1999
08/663,674 06/14/1996	Processes for the High-Yield Diastereoselective Synthesis of Dideoxynucleosides	6,005,097 12/21/1999
09/977,659 10/15/2001	Modified Prodrug Forms of AP/AMP	6,458,816 10/01/2002
10/461,282 06/13/2003	Water-Soluble SHPS as Novel Alkylating Agents	6,855,695 02/15/2005
09/645,415 08/24/2000	Compositions and Methods for Tumor-Targeted Delivery of Effector Molecules	6,962,696 11/08/2005
11/232,252 09/21/2005	Phosphate-Bearing Prodrugs of Sulfonyl Hydrazines as Hypoxia-Selective Antineoplastic Agents	7,405,317 07/29/2008
11/082,544 03/17/2005	Compositions and Methods for Tumor-Targeted Delivery of Effector Molecules	7,452,531 11/18/2008
10/593,217 09/15/2006	Combination Therapy Comprising Cloretazine	7,605,137 10/20/2009
US9709486 06/02/1997	Process for High-Yield Diastereoselective of Synthesis of Dideoxynucleosides	
US9809750 05/14/1998	Prodrug Forms of Ribonucleotide Reductase Inhibitors 3-AP and 3-AMP	
US9809803 05/14/1998	Process for the Synthesis of Ribonucleotide Reductase Inhibitors 3-AP and 3-AMP	

**EXHIBIT 1**

PATENT  
Customer No. 22,852

<b>Appln. No./ Appln. Date</b>	<b>Title</b>	<b>Patent No./Date</b>
US0132085 10/15/2001	Modified Prodrug Forms of AP/AMP	
US0415547 05/18/2004	Water-Soluble SHPS as Novel Alkylating Agents	
US0510152 09/15/2006	Combination Therapy Comprising Cloretazine	
US0533641 09/21/2005	Phosphate-Bearing Prodrugs of Sulfonyl Hydrazines as Hypoxia- Selective Antineoplastic Agents	